A new principle of retinoscopy proposes that the endpoint of neutralization be placed at infinity rather than into the aperture of the retinoscope. The advantages of the method are (1) the pupillary reflex is sharply defined and enhanced at neutralization, (2) the pupillary reflex width is equal to the diameter of the smallest aperture of the observation system, (3) the relative speed of the pupillary reflex is equal to 1, that is, the speed of the reflex is that of the scanning speed, and (4) neutralization at infinity is independent of the observation distance. The lens used gives the "net" retinoscopy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archopht.1984.01040031138042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders.
CNS Neurosci Ther
November 2024
Department of Neurology, Huashan Hospital, Fudan University and Institute of Neurology, Fudan University, Shanghai, China.
Article Synopsis
- NMOSD is a rare autoimmune disease affecting the CNS, and this study is the first Phase I clinical trial in Chinese patients testing the safety and efficacy of a new drug called BAT4406F, an anti-CD20 monoclonal antibody.
- The study involved 15 patients who received different doses of BAT4406F, with results showing no dose-limiting toxicities and mostly mild side effects, indicating a favorable safety profile.
- The drug demonstrated effective B-cell depletion, important for treating NMOSD, with a nonlinear pharmacokinetic profile and longer elimination half-life, suggesting promising therapeutic potential.
Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 Study.
J Clin Pharmacol
October 2024
Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
CT-P47 is a candidate biosimilar of tocilizumab. This 12-week, randomized, double-blind, parallel-design, phase 1 study aimed to demonstrate pharmacokinetic (PK) equivalence of CT-P47 and reference tocilizumab. Participants were healthy Japanese adults aged 18-55 years.
View Article and Find Full Text PDFPharmacokinetic comparison of subcutaneously administered CT-P13 (biosimilar of infliximab) via autoinjector and pre-filled syringe in healthy participants.
Clin Transl Sci
October 2024
Clinical Trials Center, Chungnam National University Hospital, Daejeon, Korea.
Article Synopsis
- CT-P13 is a biosimilar used to treat inflammatory diseases by providing an alternative to the traditional intravenous administration with a subcutaneous formulation delivered via autoinjector.
- A clinical study with 147 participants compared the pharmacokinetics and safety of CT-P13 administered using an autoinjector versus a pre-filled syringe, finding they had comparable serum concentration profiles.
- Both administration methods showed similar levels of immunogenicity, with no significant safety differences, confirming that both are effective and well-tolerated options for patients.
Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
J Infect
November 2024
Infectious Diseases Division, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Background: The clinical effectiveness of early therapies for mild-to-moderate COVID-19, comparing antivirals and monoclonal antibodies (mAbs) during the Omicron era, has not been conclusively assessed through a post-approval comparative trial. We present a pooled analysis of two randomized clinical trials conducted during Omicron waves.
Methods: The MANTICO2/MONET trial is a pooled analysis of two multicentric, independent, phase-4, three-arm, superiority, randomized, open-label trials.
New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double-Blind, Parallel-Group, Single-Dose Trial in Healthy Subjects.
Clin Pharmacol Drug Dev
December 2024
SocraMetrics GmbH, Erfurt, Germany.
Article Synopsis
- The RUSTIC trial evaluated the pharmacokinetic (PK) similarity of the proposed ustekinumab biosimilar FYB202 with the EU-approved and US-licensed versions after a single 45-mg injection to 491 healthy adults.
- Results showed that all comparisons of PK characteristics were similar, as the concentration measurements fell within the accepted range of 80%-125%.
- Safety analyses indicated that FYB202 had a lower rate of positive antidrug antibody results compared to reference drugs, supporting its marketing authorization alongside further studies in plaque psoriasis patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!